Table 1 TP53 mutation status, CDKN2A/p16 loss, and EC50 values ± standard error of the mean (SEM) of LY2603618/Rabusertib treatment per cell line

From: Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death

Cell line

TP53 mutationa

CDKN2A (p16) loss

EC50 (µM) LY2603618/ Rabusertib

UM-SCC-22A

g. 13419A>G

g. 14754+1G>T

Double loss

0.045 ± 0.008

UM-SCC-38

g. 13075G>T

Loss

0.073 ± 0.027

VU-SCC-OE

g. 11727_14754del

Double loss

0.160 ± 0.047

VU-SCC-120

g. 13160/13161 GC>TT

g. 13206G>A

Double loss

0.322 ± 0.035

UM-SCC-47

–

–

0.502 ± 0.001

FaDu

g. 14070G>T

Loss

0.598 ± 0.071

UT-SCC-45

–

–

0.686 ± 0.099

VU-SCC-096

g. 13338A>T

Loss

0.751 ± 0.133

UD-SCC-2

–

Loss

0.800 ± 0.112

VU-SCC-147

g. 14097T>G

–

2.225 ± 0.745

  1. aIARC TP53 Database Download TP53 Somatic R12 Genbank: X54156, published in Martens-de Kemp et al.26
Back to article page